Active ingredientEvogliptin TartrateCat. No. P-E145-001CAS 1222102-51-3Family · Pharmaceutical analytical standards
Evogliptin
A DPP-4 inhibitor (gliptin) for type 2 diabetes: it boosts the action of gut hormones that stimulate insulin. Developed in South Korea, it received its first approval in 2015, in its home country. This family brings together the active ingredient, labelled standards and other impurities.
Did you know?An antidiabetic put to the test on the heart: after laboratory studies on the aortic valve, in 2022 it entered a clinical trial to see whether it slows valve calcification, for which no drug existed.
Go to the active ingredient →Active ingredientEvogliptin TartrateCat. No. P-E145-001CAS 1222102-51-3
Isotopically labelledEvogliptin-d9 L-TartrateCat. No. P-E145-003
Impurity2,5-Difluorophenyl Evogliptin TartrateCat. No. P-E145-004
Impurity3,4-Difluorophenyl Evogliptin TartrateCat. No. P-E145-005
Impurity3-Ethylamino Evogliptin TartrateCat. No. P-E145-006
ImpurityEvogliptin Impurity 1Cat. No. P-E145-007
ImpurityEvogliptin Impurity 2Cat. No. P-E145-008
ImpurityEvogliptin Impurity 3Cat. No. P-E145-009
ImpurityEvogliptin Impurity 4Cat. No. P-E145-010
ImpurityEvogliptin Impurity 5Cat. No. P-E145-011No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.